Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The treatment landscape of renal cell carcinoma is rapidly evolving, especially with the introduction and approval of immune checkpoint inhibitor combination therapies. Clinical trial data show substantial improvements in patient outcomes, and now results in the real-world setting support the use of these combinations.
Genetics has a role in predisposition towards prostate cancer, and an accurate prediction of prostate cancer risk can be made using polygenic risk scores. New evidence suggests that this risk is modifiable through lifestyle changes, but only in men at a high genetic risk of developing prostate cancer.
Stage I testicular germ cell tumour is restricted to the testicle and can be mostly cured by orchiectomy; however, many patients experience tumour relapse. In this Review, the authors describe advantages and limitations of the currently available predictive biomarkers of relapse in germ cell tumours, and discuss the need to identify new biomarkers to avoid patient overtreatment.
Premature ejaculation is a male disorder causing distress, bother, frustration and/or avoidance of sexual intimacy. Currently available therapies are not lasting and only mildly effective. In this Review, the authors summarize currently available approved and off-label treatments for premature ejaculation, and comprehensively discuss emerging therapeutic options.
Lower urinary tract disorders (LUTDs) are common in the elderly, owing to age-related dysfunction of the lower urinary tract (LUT). An endogenous inhibitor of purine nucleoside phosphorylase, 8-aminoguanine, has been shown to reverse the effects of ageing on LUT biochemistry, structure and function, offering a novel potential treatment for LUTDs.
